期刊
JOURNAL OF RADIATION ONCOLOGY
卷 2, 期 4, 页码 369-379出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s13566-013-0125-4
关键词
Pancreatic cancer; PARP; Immunotherapy; Stereotactic; Radiation; Abscopal
类别
Currently, pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease despite advances in multimodality therapy. Themajority of patientswith PDAC present with locally advanced or metastatic disease, and additional therapies or treatment paradigms are needed to improve progression-free survival and overall survival. Alternate therapies, such as a nanoparticle albumin-bound form of paclitaxel, epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, and poly(ADP-ribose) polymerase (PARP) 1/2 inhibitors have been investigated for potential synergy with systemic agents in PDAC. Here, we review the current status of radiotherapy combined with systemic therapies for pancreatic cancer, with a focus on these targeted agents, novel immunotherapies, and discussion of the Abscopal effect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据